Detalhe da pesquisa
1.
AAV9 delivering a modified human Mullerian inhibiting substance as a gene therapy in patient-derived xenografts of ovarian cancer.
Proc Natl Acad Sci U S A
; 112(32): E4418-27, 2015 Aug 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-26216943